AstraZeneca India gets CDSCO approval for additional indication for Osimertinib in unresectable EGFR-mutated lung cancer Read more
AstraZeneca India receives CDSCO approval for Durvalumab for specified additional indication Read more
AbbVie’s $10.1 bn Immunogen deal fortifies oncology portfolio, signals big pharma’s ADC investment surge: GlobalData Read more
AstraZeneca’s Durvalumab gets CDSCO nod to treat locally advanced or metastatic biliary tract cancer Read more